• Corpus ID: 45125545

Do adverse respiratory effects of beta2-agonists contribute to asthma morbidity and mortality?

  title={Do adverse respiratory effects of beta2-agonists contribute to asthma morbidity and mortality?},
  author={Colin Deeney},
  journal={The Pharmaceutical Journal},
  • C. Deeney
  • Published 2006
  • Medicine
  • The Pharmaceutical Journal
Short-acting beta2-agonists (SABAs) have been used as first line therapy for the acute relief of bronchoconstriction in asthma for several decades. However, antiinflammatory therapies are now considered the cornerstone of chronic asthma management. Therefore, it is now recommended that unless individual patients are shown to benefit from regular treatment SABAs are used only when required for acute symptoms. Indeed, regular use is usually seen as an indication of poor asthma control and a need… 
1 Citations
Doxofylline is a novel bronchodilator xanthine drug that offers an opportunity to improve tolerability of methylxanthines and its clinical efficacy in relieving airway obstruction and tolerability in paediatric patients is shown.


Polymorphism of the β2-adrenoceptor and the response to long-term β2-agonist therapy in asthma
An analysis of the β2-adrenoceptor genotypes in 64 asthmatics to establish whether changes in asthma control during the earlier study were influenced by β1-ad Renoceptor polymorphism, and the response to long-termβ2-agonist therapy in asthma.
An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta 2-agonist.
This study suggests that even a high dose of an inhaled glucocorticoid fails to prevent the loss of bronchoprotection produced by regular beta 2-agonist therapy, and suggests an improvement in airway hyperresponsiveness with budesonide therapy.
Regular formoterol treatment in mild asthma. Effect on bronchial responsiveness during and after treatment.
Examination of the effect of an inhaled long-acting beta 2-adrenoceptor agonist, formoterol for 2 wk on airway function and responsiveness in 17 subjects with mild asthma found it to be effective in single doses in the prevention of methacholine-induced bronchoconstriction.
Effects of terbutaline and budesonide on sputum cells and bronchial hyperresponsiveness in asthma.
The hypothesis that short-acting beta-agonists have a permissive effect on airway inflammation and that when used in high dose there may be an unfavorable interaction with inhaled corticosteroids is supported.
Tolerance to the Nonbronchodilator Effects of Inhaled β2-Agonists in Asthma
This randomized, double-blind, crossover study investigated whether tolerance develops to the protective effect of inhaled terbutaline on airway responsiveness to the bronchoconstrictors methacholine and AMP during sustained treatment with terbutalin.
Long-Acting β2-Agonist Monotherapy vs Continued Therapy With Inhaled Corticosteroids in Patients With Persistent Asthma: A Randomized Controlled Trial
Patients with persistent asthma well controlled by low doses of triamcinolone cannot be switched to salmeterol monotherapy without risk of clinically significant loss of asthma control.
Effect of regular salmeterol treatment on albuterol-induced bronchoprotection in mild asthma.
Regular salmeterol treatment led to loss of bronchoprotection by albuterol to MCh but not to AMP challenge, implying an absence of mast cell beta 2-adrenoceptor downregulation with regular sal meterol therapy.
Tolerance to beta-agonists during acute bronchoconstriction.
Investigating whether bronchodilator tolerance can be demonstrated during acute bronchoconstriction finds that continuous treatment with inhaled beta-agonists may lead to a reduced response to emergency beta-agonist treatment during asthma exacerbations.
Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network.
In patients with mild asthma, neither deleterious nor beneficial effects derived from the regular use of inhaled albuterol beyond those derived from use of the drug as needed are found.
The long-acting beta2-agonist salmeterol xinafoate: effects on airway inflammation in asthma.
Regular treatment with salmeterol improves clinical indices of asthma but has no effect on the underlying inflammatory process, strengthening guideline recommendations that long-acting beta2-agonists should not be prescribed as sole antiasthma medication.